Literature DB >> 16802726

N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease.

Alessandro P Burlina1, Vanni Ferrari, Alberto B Burlina, Mario Ermani, Odile Boespflug-Tanguy, Enrico Bertini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16802726     DOI： 10.1007/0-387-30172-0_26

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  3 in total

1.  N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate.

Authors:  Julia Lodder-Gadaczek; Ivonne Becker; Volkmar Gieselmann; Lihua Wang-Eckhardt; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

2.  Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.

Authors:  Fanny Mochel; Nadège Boildieu; Julie Barritault; Catherine Sarret; Eleonore Eymard-Pierre; François Seguin; Raphael Schiffmann; Odile Boespflug-Tanguy
Journal:  Biochim Biophys Acta       Date:  2010-07-13

3.  Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseases.

Authors:  F Mochel; U F H Engelke; J Barritault; B Yang; N H McNeill; J N Thompson; A Vanderver; N I Wolf; M A Willemsen; F W Verheijen; F Seguin; R A Wevers; R Schiffmann
Journal:  Neurology       Date:  2010-01-26       Impact factor: 9.910
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.